Cargando…
Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent
Autores principales: | Vatsa, Rakhee, Sood, Ashwani |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257099/ https://www.ncbi.nlm.nih.gov/pubmed/35345242 http://dx.doi.org/10.4103/ijmr.IJMR_2377_19 |
Ejemplares similares
-
Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging
por: Shi, Jiyun, et al.
Publicado: (2016) -
Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023) -
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT
por: Zhou, Yang, et al.
Publicado: (2011) -
Advancing theranostics with tumor-targeting peptides for precision otolaryngology
por: Wright, Chadwick L., et al.
Publicado: (2016) -
Evaluation of Radioiodinated Fluoronicotinamide/Fluoropicolinamide-Benzamide Derivatives as Theranostic Agents for Melanoma
por: Chen, Chao-Cheng, et al.
Publicado: (2020)